

Figure S1. Gold standard TTC for identifying MCAO model success. (A) Representative pictures of each group's TTC-stained brain slices. The normal portions were red, whereas the infarct areas were shown in white. (B) A quantitative examination of each group's cerebral infarction volumes (n = 8). Values were expressed as mean \pm SD (n = 5). *P < 0.05 and **P < 0.01 vs. Sham group, ##P < 0.01 vs. Model group.



Figure S2. Each group involves in the APD via ex vivo optical mapping. (A) Quantification of APD90 in six groups. (B) Calculation of velocity in AP phase each left atrium of six groups. (C) Calculation of rise time in AP phase each left atrium of six groups. (D) Calculation of IQR in AP phase each left atrium of three groups. (E) Statistical results of APD 30/80 in six groups. Values were expressed as mean \pm SD (n = 5). *P < 0.05 and **P < 0.01 vs. Sham group, #P < 0.05 and ##P < 0.01 vs. Model group.



Figure S3. Each group involves in the CaT alterations via ex vivo optical mapping. (A) Quantification of CaT90 in six groups. (B) Calculation of velocity in Ca release each left atrium of six groups. (C) Calculation of rise time in Ca release each left atrium of six groups. (D) Calculation of IQR in Ca release each left atrium of six groups. Values were expressed as mean \pm SD (n = 5). *P < 0.05 and **P < 0.01 vs. Sham group, #P < 0.05 and ##P < 0.01 vs. Model group.



Figure S4. RT-PCR verification results of RNA-seq. (A-D) The mRNA expression levels of the CHRM1, INA, SLC6A15, and SYT4. Values are given as mean \pm SD (n = 3, *P < 0.05 and **P < 0.01 vs. Sham group, #P < 0.05 and ##P < 0.01 vs. Model group).



Figure S5. Statistical data for WK's active compounds. (A) Combined data of ICa-L recorded

during exposure to Tanshinone-IIA (10 μ mol/L), Nardosinone (10 μ mol/L), Cryptotanshinone (10 μ mol/L), Ginsenoside Re (10 μ mol/L), Ginsenoside Rb1 (10 μ mol/L), Ginsenoside Rg1 (10 μ mol/L), Atractylenolide (10 μ mol/L) and fushing under Control conditions. (B) Combined data of I_{Ca-L} recorded during exposure to Tanshinone-IIA (50 μ mol/L), Nardosinone (50 μ mol/L), Cryptotanshinone (50 μ mol/L), Ginsenoside Re (50 μ mol/L), Ginsenoside Rg1 (50 μ mol/L), Ginsenoside Rg1 (50 μ mol/L), Atractylenolide (50 μ mol/L), Ginsenoside Rg1 (50 μ mol/L), Atractylenolide (50 μ mol/L), Ginsenoside Rg1 (50 μ mol/L), Atractylenolide (50 μ mol/L) and fushing under Control conditions. (P>0.05)

| Primer name | | Primer sequence (5'-3') |
|-------------|---------|---------------------------|
| INA | FORWARD | GGCTGAATCCACTTCCCAATCCC |
| INA | REVERSE | TCTTCCTCCTCCTCCTCCTCCTC |
| IFI44 | FORWARD | AGTGCTCCGACTGCCTTCTCTC |
| IFI44 | FORWARD | ACCAGGTCTCCATACGGCTTGTAG |
| CHRM1 | FORWARD | GCCGCCTTCTACCTCCCTGTC |
| CHRM1 | REVERSE | CTGCTGCCGCCACCACCTTTG |
| SLC6A15 | FORWARD | TTGGGTTTGGGATTTGGTGGAGTC |
| SLC6A15 | REVERSE | ACAGCGTCGAAGTGGCAGTTG |
| SYT4 | FORWARD | ATCAGTCCACTACAAACACGCTCAC |
| SYT4 | REVERSE | TCTTCTTGGCATGGTACAGGTTCAC |
| CHAT | FORWARD | AGCGAGCCTTGTTGACATGA |
| CHAT | REVERSE | GATTGCTTGGCTTGGTTGGG |
| SLC5A7 | FORWARD | CCAAGACCAAGGAGGAAGCAGAC |
| SLC5A7 | REVERSE | GCACCAAGCCCAAAGAAGGAAATG |
| CHRM4 | FORWARD | CCGCACTACTAAGATGGCAGGTC |
| CHRM4 | REVERSE | GGCAGGTAGAAGGCAGCAATGG |
| CACNA1B | FORWARD | GCCTTCGGGGTGTTGAACTA |
| CACNA1B | REVERSE | GTTCGTTTCCGCAATCTCCG |
| ACHE | FORWARD | AACAGAAGCCTCCGGATTGG |
| ACHE | REVERSE | ACCGACTTCCGAGCTCTCTA |
| CACNB1 | FORWARD | AGGGCAAATACAGCAAGAGGAAAGG |
| CACNB1 | REVERSE | GTTGGATGTGGTATCTGAGGAGGTG |
| ATP2A3 | FORWARD | AGTCGGCAGCGGAGATGGTTC |
| ATP2A3 | REVERSE | TTGGAGGAGATGAGGTAGCGGATG |
| GNG3 | FORWARD | AGCACGCAAGATGGTGGAACAG |
| GNG3 | REVERSE | GGGCATCACAGTAAGTCATCAGGTC |
| CHRM3 | FORWARD | CGGTCGCTGTCACTTCTGGTTC |
| CHRM3 | REVERSE | GTCGCTGCTGCTGTGGTCTTG |
| GAPDH | FORWARD | ACGGCAAGTTCAACGGCACAG |
| GAPDH | REVERSE | CGACATACTCAGCACCAGCATCAC |

Supplementary data: Table 1. Primer sequences of rat genes.

Method

Sample collection and preparation

RNA quantification and qualification

RNA integrity was assessed using the RNA Nano 6000 Assay Kit of the Bioanalyzer 2100 system (Agilent Technologies, CA, USA).

Library preparation for Transcriptome sequencing

Total RNA was used as input material for the RNA sample preparations. Briefly, mRNA was purified from total RNA using poly-T oligo-attached magnetic beads. Fragmentation was carried out using divalent cations under elevated temperature in First Strand Synthesis Reaction Buffer(5X). First strand cDNA was synthesized using random hexamer primer and M-MuLV Reverse Transcriptase (RNase H-). Second strand cDNA synthesis was subsequently performed using DNA Polymerase I and RNase H. Remaining overhangs were converted into blunt ends via exonuclease/polymerase activities. After adenylation of 3' ends of DNA fragments, Adaptor with hairpin loop structure were ligated to prepare for hybridization. In order to select cDNA fragments of preferentially 370~420 bp in length, the library fragments were purified with AMPure XP system (Beckman Coulter, Beverly, USA). Then PCR was performed with Phusion High-Fidelity DNA polymerase, Universal PCR primers and Index (X) Primer. At last, PCR products were purified (AMPure XP system) and library quality was assessed on the Agilent Bioanalyzer 2100 system.

Clustering and sequencing (Novogene Experimental Department)

The clustering of the index-coded samples was performed on a cBot Cluster Generation System using TruSeq PE Cluster Kit v3-cBot-HS (Illumia) according to the manufacturer's instructions. After cluster generation, the library preparations were sequenced on an Illumina Novaseq platform and 150 bp paired-end reads were generated.

Data Analysis

Quality control

Raw data (raw reads) of fastq format were firstly processed through fastp software. In this step, clean data (clean reads) were obtained by removing reads containing adapter, reads containing ploy-N and low-quality reads from raw data. At the same time, Q20, Q30 and GC content the clean data were calculated. All the downstream analyses were based on the clean data with high quality.

Reads mapping to the reference genome

Reference genome and gene model annotation files were downloaded from genome website directly. Index of the reference genome was built using Hisat2 v2.0.5 and paired-end clean reads were aligned to the reference genome using Hisat2 v2.0.5. We selected Hisat2 as the mapping tool for that Hisat2 can generate a database of splice junctions based on the gene model annotation file and thus a better mapping result than other non-splice mapping tools.

Novel transcripts prediction

The mapped reads of each sample were assembled by StringTie (v1.3.3b) in a reference-based approach. StringTie uses a novel network flow algorithm as well as an optional de novo assembly step to assemble and quantitate full length transcripts

representing multiple splice variants for each gene locus.

Quantification of gene expression level

featureCounts v1.5.0-p3 was used to count the reads numbers mapped to each gene. And then FPKM of each gene was calculated based on the length of the gene and reads count mapped to this gene.

FPKM, expected number of Fragments Per Kilobase of transcript sequence per Millions base pairs sequenced, considers the effect of sequencing depth and gene length for the reads count at the same time, and is currently the most commonly used method for estimating gene expression levels.



2. GC content distribution



3. Sequencing data filtering



The Sequence Read Archive (SRA) is summarized in the : https://www.ncbi.nlm.nih.gov/sra/PRJNA1157589.